More Post from the Author
- StarKist, Feed the Children, and Feed 479 Unite to Support 400 Northwest Arkansas Families with Food and Resources
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of EmCentrix Customers Whose Data May Have Been Compromised
- McLaughlin Poll: Voters Overwhelmingly Reject Excessive Government Mandates and Regulatory Red Tape Targeting the Individual Health Care Marketplace
- 50+ Environmental and Public Interest Groups Oppose CA Oil Refiner Bailout, Urge State to Stand Strong on Accountability, Says Consumer Watchdog
- 88 Dragons PR Inc: HISTORIC PEACE AGREEMENT SIGNED BETWEEN DEMOCRATIC REPUBLIC OF CONGO AND RWANDA
Fangzhou Inc. Announces Inclusion as a Constituent of the Hang Seng Composite Index
HONG KONG, Feb. 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company has been selected and will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited, with effect from March 10, 2025.
The Company is of the view that inclusion as a constituent of the Hang Seng Composite Index has the potential to elevate its profile among a broader spectrum of investors and enhance the Company's recognition in the capital markets, while creating opportunities for customers, partners, and investors to engage with the Company's innovative Internet healthcare solutions. For further details, please refer to the relevant index notice(s) published on the website of Hang Seng Indexes Company Limited (https://www.hsi.com.hk).
About the Hang Seng Composite Index
The Hang Seng Composite Index is a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited and can be used as a basis for index funds, mutual funds as well as performance benchmarks.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit https://investors.jianke.com.
Media Contact
For inquiries or interview requests, please contact:
Xingwei Zhao
Associate Director of Public Relations
Email:[emailprotected]
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
SOURCE Fangzhou Inc.
More Post from the Author
- StarKist, Feed the Children, and Feed 479 Unite to Support 400 Northwest Arkansas Families with Food and Resources
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of EmCentrix Customers Whose Data May Have Been Compromised
- McLaughlin Poll: Voters Overwhelmingly Reject Excessive Government Mandates and Regulatory Red Tape Targeting the Individual Health Care Marketplace
- 50+ Environmental and Public Interest Groups Oppose CA Oil Refiner Bailout, Urge State to Stand Strong on Accountability, Says Consumer Watchdog
- 88 Dragons PR Inc: HISTORIC PEACE AGREEMENT SIGNED BETWEEN DEMOCRATIC REPUBLIC OF CONGO AND RWANDA